Need Help?

Massive Genomic Rearrangment Acquired in a Single Catastrophic Event During Cancer Development

Cancer is driven by mutation. Using Agilent exome hybridisation capture and Illumina GA massively parallel sequencing technology, we aim to sequence ~1600 microRNAs plus the protein coding genome of 25 matched human renal cancer samples. Bespoke algorithms are being developed to identify the somatically acquired point mutations, insertions and deletions in these samples. This project will give unprecedented insights into mutational processes, cellular repair pathways and gene networks associated with renal cancer development.Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 25 renal cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 50 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001000002 Illumina Genome Analyzer Illumina Genome Analyzer II 11
Publications Citations
Massive genomic rearrangement acquired in a single catastrophic event during cancer development.
Cell 144: 2011 27-40
ShatterProof: operational detection and quantification of chromothripsis.
BMC Bioinformatics 15: 2014 78
Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling.
Mol Oncol 17: 2023 1343-1355